The purpose of the Core C Biostatistics is to assure that studies conducted through this P01 to develop novel therapeutic strategies in myeloid malignancies are conceptualized under robust principles of statistical design and are analyzed appropriately.
Specific Aim 1. To provide biostatistical collaboration for clinical research protocols. Biologically motivated clinical research protocols in this P01 are conducted through Core D as in vivo human experiments on behalf of the projects. Support by Core C includes all aspects of the design, conduct, analysis, and reporting of the clinical studies, as well as oversight of the electronic data capture mechanism.
Specific Aim 2. To provide biostatistical collaboration for the laboratory research studies. This includes all aspects of the design, conduct, analysis, and reporting of such studies, as well as the association between laboratory results and clinical outcomes both in prospective clinical studies of new agents and in retrospective studies involving sequencing and identification of mutations and their associations with both clinical features of disease and with clinical outcomes. 3. To provide biostatistical collaboration for animal studies, including all aspects of the design and analysis of murine studies.

Public Health Relevance

Core C Biostatistics will assure that all experiments conducted through this P01 in myeloid malignancies will have robust statistical designs and appropriate statistical analysis, to optimize our ability to identify novel therapeutic strategies and improve our understanding of the biology of myeloid malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-16A1
Application #
8666235
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
1997-04-25
Project End
2019-08-31
Budget Start
2014-09-16
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$109,097
Indirect Cost
$15,307
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Sridhar, Radhakrishnan; Takei, Hisashi; Syed, Riyaz et al. (2018) Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP?. Molecules 23:
Chu, S Haihua; Song, Evelyn J; Chabon, Jonathan R et al. (2018) Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv 2:2478-2490
Wang, Jinhua; Erazo, Tatiana; Ferguson, Fleur M et al. (2018) Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol 13:2438-2448
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Cortes, Jorge E; Douglas Smith, B; Wang, Eunice S et al. (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 93:1301-1310
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Cusan, Monica; Cai, Sheng F; Mohammad, Helai P et al. (2018) LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBP?-dependent enhancers in AML. Blood 131:1730-1742
Postalcioglu, Merve; Kim, Haesook T; Obut, Faruk et al. (2018) Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:2344-2353
DiNardo, Courtney D; Pratz, Keith; Pullarkat, Vinod et al. (2018) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood :

Showing the most recent 10 out of 376 publications